Neufil

প্রাপ্তবয়স্ক:

Cancer patients receiving myelosuppressive chemotherapy, or induction and/or consolidation chemotherapy for AML: The usual dose of Filgrastim is 0.5 MU (5 mcg)/kg/day, given as a single daily subcutaneous injection or as an intravenous infusion over 30 minutes. The first dose should not be given within 24 hours of cytotoxic chemotherapy. Keep going until the neutrophil count is back in the normal range, which usually takes 14 days (up to 38 days in AML). Cancer patients undergoing bone marrow transplantation (BMT): The usual dose of Filgrastim after bone marrow transplantation (BMT) is 1.0 MU (10 mcg)/kg/day, given as an intravenous infusion lasting no longer than 24 hours. Give the first dose at least 24 hours after cytotoxic chemotherapy and at least 24 hours after the bone marrow transplantation. The dose should be adjusted according to the absolute neutrophil count (ANC). Patients undergoing autologous peripheral blood progenitor cell (PBPC) collection and therapy: The usual dose of Filgrastim for mobilising autologous PBPC is 1.0 MU (10 mcg)/kg/day, given as a subcutaneous injection for 5 to 7 days. Start Filgrastim at least 4 days before the first leukapheresis procedure and continue until the last one. Stop Filgrastim if the white blood cell (WBC) count rises above 100,000/mm³. Patients with severe chronic neutropenia: The usual starting dose in patients with congenital neutropenia is 0.6 MU (6 mcg)/kg as a subcutaneous injection twice daily. In patients with idiopathic or cyclic neutropenia, it is 0.5 MU (5 mcg)/kg as a single daily subcutaneous injection. The dose should be adjusted according to the ANC and the complete blood count (CBC). Patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome): The usual dose of Filgrastim is 1.0 MU (10 mcg)/kg as a single daily subcutaneous injection for patients exposed to myelosuppressive doses of radiation. Patients with HIV infection: The usual starting dose of Filgrastim is 0.1 MU (1.0 mcg)/kg/day, given daily as a subcutaneous injection. The dose is increased step by step to a maximum of 0.4 MU (4 mcg)/kg/day until a normal neutrophil count is reached and can be maintained (ANC above 2.0 x 10 9 /I), or as directed by the registered physicians.